MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

CureVac NV

Suletud

2.72 -2.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.72

Max

2.8

Põhinäitajad

By Trading Economics

Sissetulek

443M

371M

Müük

479M

494M

P/E

Sektori keskmine

5.431

63.778

Aktsiakasum

1.5

Kasumimarginaal

75.029

Töötajad

999

EBITDA

441M

375M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+233.94% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. apr 2025

Turustatistika

By TradingEconomics

Turukapital

664M

Eelmine avamishind

4.88

Eelmine sulgemishind

2.72

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

CureVac NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. juuli 2024, 09:14 UTC

Omandamised, ülevõtmised, äriostud

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3. juuli 2024, 14:18 UTC

Omandamised, ülevõtmised, äriostud

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3. juuli 2024, 09:38 UTC

Market Talk

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Võrdlus sarnastega

Hinnamuutus

CureVac NV Prognoos

Hinnasiht

By TipRanks

233.94% tõus

12 kuu keskmine prognoos

Keskmine 9.25 USD  233.94%

Kõrge 16 USD

Madal 2.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi CureVac NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

1

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

2.72 / 2.905Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.